Anti-SLC34A2 monoclonal antibody and application thereof
By developing novel anti-SLC34A2 antibodies with high binding affinity and strong ADCC activity, the shortcomings of existing antibodies in the treatment of cancers overexpressing the SLC34A2 protein were solved, and more efficient therapeutic effects were achieved.
CN119948054APending Publication Date: 2025-05-06LANOVA MEDICINES DEV CO LTD
4 Cites 2 Cited by
Patent Information
- Application Number
- CN202380053616.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-22
- Filing Date
- 2023-06-21
- Publication Date
- 2025-05-06
AI Technical Summary
Technical Problem
Existing antibodies against the SLC34A2 protein have insufficient binding affinity, cross-species reactivity, ADCC and cytotoxicity, making it difficult to effectively treat cancers that overexpress the protein.
Method used
A novel anti-SLC34A2 antibody has been developed, which contains specific heavy and light chain variable regions, has high binding affinity, and is able to effectively mediate antibody-dependent cytotoxicity (ADCC) and induce cytotoxicity.
Benefits of technology
Compared with the benchmark antibodies XMT-1536 and RG-7599, the novel antibodies show higher binding affinity, greatly improved cross-species reactivity, stronger ADCC and cytotoxicity, and are suitable for the treatment of diseases such as cancer.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides an antibody or fragment thereof having binding specificity for human solute carrier 34A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 with high affinity, and can mediate antibody dependent cytotoxicity (ADCC) and effectively induce endocytosis. Methods and uses for treating cancer are also provided.
Need to check novelty before this filing date? Find Prior Art